Hoosier Cancer Research Network will have a strong presence at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, with four investigator-initiated studies featured. Presented through Trials in Progress posters and a Rapid Oral Abstract Session, these studies reflect HCRN’s continued commitment to supporting collaborative, investigator-initiated research aimed at improving treatment options and outcomes for patients.
HCRN-GU23-633
HCRN study, HCRN-GU23-633, will be presented by Jason Robert Brown, MD, PhD, of University Hospitals Seidman Cancer Center, as a Trials in Progress poster. The study, “A phase II study of zanzalintinib for patients with advanced urothelial carcinoma following prior therapy,” is led by Guru P. Sonpavde, MD, of AdventHealth Cancer Institute.
Session Details:
- Presentation Title: A phase II study of zanzalintinib for patients with advanced urothelial carcinoma following prior therapy
- Abstract: TPS889
- Poster Board: M17
- Presenter: Jason Robert Brown, MD, PhD
See abstract: https://www.asco.org/abstracts-presentations/257181
HCRN-GU22-598
HCRN-GU22-598, will be presented by Eric James Miller, MD, of Mount Sinai Tisch Cancer Center, as a Trials in Progress poster. The study, “Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder,” is led by Matthew Galsky, MD, of the Icahn School of Medicine at Mount Sinai.
Session Details:
- Presentation Title: Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder
- Abstract: TPS891
- Presenter: Eric James Miller, MD
See abstract: https://www.asco.org/abstracts-presentations/257183
HCRN-GU20-444 
HCRN-GU20-444, will be presented by Jonathan F. Anker, MD, PhD, of Mount Sinai Tisch Cancer Center, during the Rapid Oral Abstract Session. The study, “Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444),” is led by Matthew Galsky, MD, of the Icahn School of Medicine at Mount Sinai.
Session Details:
- Presentation Title: Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444)
- Abstract: 737
- Presenter: Jonathan F. Anker, MD, PhD
See abstract: https://www.asco.org/abstracts-presentations/257349
HCRN-GU21-517
HCRN-GU21-517 will be presented by Justine Ann Panian, MD, of UC San Diego Health during Poster Session A. The study, “A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis” is led by Rana McKay, MD, FASCO, also of UC San Diego Health.
Session Details:
- Presentation Title: A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis
- Abstract: 187
- Presenter: Justine Ann Panian, MD
See abstract: https://www.asco.org/abstracts-presentations/256487
